Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: February 15, 2000
Last updated: June 23, 2005
Last verified: November 2000

February 15, 2000
June 23, 2005
October 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004585 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followed by the Triple Nucleoside Combination Tablet (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) BID Plus Sustiva (Efavirenz) 600mg QD for 24 Weeks in HIV-Infected Adults

The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.

Patients take open-label Combivir plus abacavir plus efavirenz for 48 weeks. [AS PER AMENDMENT 4/20/00: Patients taking Combivir plus abacavir at Week 24 receive the triple-nucleoside-combination tablet (TCT) (abacavir/lamivudine/zidovudine) beginning at Week 24 and continuing through Week 48, in combination with efavirenz (or nevirapine if the patient has made a protocol-allowed substitution). Patients not taking Combivir and abacavir at Week 24 will continue in the study on the substituted protocol-allowed drug regimen, provided their plasma HIV RNA is below 400 copies/ml at 24 weeks.] Following enrollment on Study Day 1, on-study evaluations (virologic and safety) are performed at Weeks 2, 4, 8, 12, 16, and then every 8 weeks through Week 48 (end of study). CD4 evaluations are performed at baseline and at Weeks 4, 8, and then every 8 weeks through Week 48. Immune reconstitution testing is performed at baseline and at Weeks 12, 24, and 48. Patients complete the PMAQ7 version 1.1 medication adherence questionnaire at Weeks 2, 8, 12, 24, and 48 (or at their last study visit). All patients are requested to return for a post-study follow-up evaluation 2 to 4 weeks after the last on-study visit. Patients must have a plasma HIV RNA less than 400 copies/ml at Week 24 in order to continue in the study.

Phase 4
Endpoint Classification: Safety Study
Primary Purpose: Treatment
HIV Infections
  • Drug: Abacavir sulfate, Lamivudine and Zidovudine
  • Drug: Lamivudine/Zidovudine
  • Drug: Abacavir sulfate
  • Drug: Efavirenz
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have HIV levels of 50,000 copies/ml or more within 21 days prior to starting treatment.
  • Are at least 18 years of age.
  • Are willing to use an effective method of birth control during the study.
  • (This study has been changed. A CD4 cell count of 50/mm3 or more within 21 days prior to starting treatment is no longer required.)

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Are pregnant.
  • Have AIDS.
  • Cannot take medications by mouth.
  • Have hepatitis and it is active.
  • Are enrolled in other investigational drug studies.
  • Are allergic to any of the study drugs.
  • Have a serious medical condition, such as heart disease.
  • Have ever taken certain anti-HIV drugs such as nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs).
  • Have ever had more than 7 days of treatment with a nucleoside reverse transcriptase inhibitor (NRTI). Patients should have no prior treatment with abacavir and no prior treatment with at least one of the following: lamivudine or zidovudine.
  • Have had radiation therapy or chemotherapy within 4 weeks prior to study entry, or plan to have such therapy during the study.
  • Have received medications that might affect the immune system, such as systemic corticosteroids, interleukins, vaccines, or interferons within 4 weeks prior to study entry.
  • Have received an HIV vaccine within 3 months prior to study entry.
  • Are taking foscarnet, hydroxyurea, or other drugs that work against HIV.
  • Have taken certain medications such as astemizole, cisapride, dihydroergotamine, ergotamine, ganciclovir, interferon-alpha, midazolam, terfenadine, and triazolam within 21 days of study entry.
  • Abuse alcohol or drugs.
  • Are unable to complete the whole study.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
307A, COL30336
Not Provided
Not Provided
Glaxo Wellcome
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
November 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP